Why is argenx stock plunging today?
argenx SE (ARGX) stock fell 15.7% to €707.4 after terminating its Phase 3 UNITY study for efgartigimod in Sjögren’s disease due to failure to meet the primary endpoint. The company also reported positive Phase 2 results for its FB102 asset in celiac disease, but this did not offset the decline. The broader market and biotech sector were also under pressure.
How this was made
The 30-second read
Why it matters
The abrupt trial halt removes a key growth catalyst, leading to a sharp share price decline.
Market read
The news drives a significant intra‑day sell‑off in ARGX and may affect sentiment across European biotech stocks.
What to watch
Positive Phase 2 celiac disease data could provide near‑term upside if investors focus on it.
Background
argenx announced the termination of its Phase 3 UNITY trial for Sjögren’s disease after an independent data monitoring committee recommendation.
Ticker impact
argenx stock fell 15.7% after terminating its Phase 3 UNITY study for Sjögren’s disease.
likely further downside as the market prices in the trial failure.
The UNITY study was a major expansion opportunity; its abrupt stop eliminates near‑term revenue upside, prompting a sell‑off.
Market effects
Biotech sector may see broader risk aversion to late‑stage trial outcomes.
European biotech stocks could face pressure amid the negative news.
Limited to biotech investors; no immediate macro impact.
Counterpoint
If the company can quickly pivot to other pipeline assets, the sell‑off may be overdone.
Key entities
- companyargenx SE
Biotech firm listed on Euronext Brussels (ticker ARGX).
- executiveLuc Truyen
Chief Medical Officer of argenx who commented on the trial outcome.
